FIELD OF THE DISCLOSURE

[0001] The present disclosure relates to cationic palladium precatalysts comprising diamino carbene ligands.

BACKGROUND OF THE DISCLOSURE

[0002] The utility of palladium-catalyzed coupling processes was quickly recognized by the synthetic community to be highly useful and as such significant effort has been invested to broaden the scope and improve the utility of such processes. The various coupling methodologies that have been established find highly valued applications in the synthesis of natural products and pharmaceuticals, ¹ as well as compounds relevant to materials chemistry. ²

[0003] The typical catalytic cycle for a Pd-catalyzed coupling proceeds through oxidative addition of the electrophilic compounds to the Pd(0) active species followed by transmetallation which is in turn followed by reductive elimination from the Pd(ll) intermediate to give the coupled product and the original Pd(0) species which re-enters the cycle. Typically, Pd(ll) pre-catalysts are employed as more stable and convenient sources of the normally air- sensitive Pd(0) active species.

SUMMARY OF THE DISCLOSURE

[0004] While Pd(ll) pre-catalysts are known in the art, cationic diamino carbene Pd(ll) pre-catalysts have not been investigated. Accordingly, the present disclosure includes a cationic palladium pre-catalyst compound of the formula I:

[Pd (X) _q (LB) _n (LBX) _t (DC)] ^r+ [Y ^m -] _P (I) wherein

DC is a diamino carbene ligand,

X is any anionic ligand,

LB is any neutral Lewis base, LBX is a combined anionic and neutral ligand,

Y is any non-coordinating anion,

q is 0 or 1 ,

n is 0 to 3,

t is 0 or 1 ,

r is 1 or 2,

m is 1 or 2,

p is 1 or 2,

wherein the sum of q + r is 2 or t + r is 2,

when t is 1 , q is 0,

when r is 1 , m and p are both 1 , and

when r is 2, either (i) m is 2 and p is 1 , or (ii) m is 1 and p is 2,

wherein when p is 2, Y is the same or different.

[0005] In another embodiment, the present disclosure also includes dimeric forms of the pre-catalyst compounds having the formula (la)

[Pd (X) _q (LB)n (LBX), (DC)] ₂ ^a+ [V-] _u [Z ² -] _y (la) wherein

DC is a diamino carbene ligand,

X is any anionic ligand,

LB is any neutral Lewis base,

LBX is a combined anionic and neutral ligand,

V is any non-coordinating mono-anion,

Z is any non-coordinating di-anion

q is 0 or 1 ,

n is 0 to 3,

t is 0 or 1 ,

a is 2 or 4,

u is 0, 2 or 4,

y is 0, 1 or 2,

wherein the sum of q + a is 3 or 4, or t + a is 3 or 4, when t is 1 , q is 0,

when a is 2, either (i) u is 2 and y is 0; or (ii) u is 0 and y is 1 ; or

when a is 4, either (i) u is 4 and y is 0; (ii) u is 2 and y is 1 ; or (iii) u is 0 and y is 2;

wherein when u is 2 or 4, V is the same or different, and

when y is 2, Z is the same or different.

[0006] In one embodiment, the compounds of the formulae (I) and (la) are chiral or achiral.

[0007] In another embodiment of the disclosure, the diamino carbene ligand is a compound of the formula (II):

R ¹ R ³

wherein

R ¹ , R ² , R ³ and R ⁴ are independently selected from H, Ci _-2 oalkyl, C _2-2 oalkenyl, C _2-20 alkynyl, C ₃ - ₂ ocycloalkyl, heteroaryl and aryl, each group being optionally substituted, or

R ¹ and R ² and/or R ³ and R ⁴ are linked to form, together with the nitrogen atom to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 3 to 20 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NCi _-6 alkyl, and/or

R ¹ and R ³ or R ² and R ⁴ are linked to form, together with the nitrogen atoms to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 3 to 20 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NCi _-6 alkyl,

the optional substituents on R , R ² , R ³ and R ⁴ are independently selected from one or more of Ci _-6 alkyl, halo, halo-substituted Ci _-6 alkyl, C3-iocycloalkyl, aryl and heteroaryl. [0008] In one embodiment, the compounds of the formula (II) are chiral or achiral.

[0009] The present disclosure also includes a method of performing metal- catalyzed organic synthesis reactions comprising contacting substrates for the organic synthesis reaction with a cationic palladium precatalyst of the formulae I or la as defined above in the presence of a base under conditions for performing the organic synthesis reaction, and optionally isolating one or more products from the organic synthesis reaction. In an embodiment of the disclosure, the organic synthesis reaction is any reaction that benefits from the presence or use of a cationic palladium precatalyst, for example, but not limited to cross-couplings. In an embodiment of the disclosure, the organic synthesis transformation is an asymmetric or chiral synthesis reaction (i.e. provides one enantiomer in excess of the other).

[0010] Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the disclosure are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] The present disclosure will now be described in greater detail with reference to the attached drawings in which:

[0012] Figure 1 is an X-ray crystal structure of precursor A in an embodiment of the disclosure. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity;

[0013] Figure 2 is an X-ray single-crystal structure of precursor B in an embodiment of the disclosure. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity; [0014] Figure 3 is an X-ray single-crystal structure of precursor C in an embodiment of the disclosure. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity;

[0015] Figure 4 is an X-ray single-crystal structure of IA in an embodiment of the disclosure. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity;

[0016] Figure 5 is an X-ray single-crystal structure of IB.OH ₂ in an embodiment of the disclosure. The unit cell contains 1 molecule of IB.OH2, 1 molecule of BF ₄ and 1 molecule of CH2CI2; only IB.OH2 is shown for clarity. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity;

[0017] Figure 6 is an X-ray single-crystal structure of IC in an embodiment of the disclosure. The unit cell contains 1 molecule of 1 C, 2 molecules of BF ₄ and 1 molecule of CH2CI2; only IC is shown for clarity. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity.

[0018] Figure 7 is an X-ray single-crystal structure of ID in an embodiment of the disclosure. The unit cell contains 1 molecule of ID, 2 molecules of BF ₄ and 1 molecule of CH2CI2; only ID is shown for clarity. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity; and

[0019] Figure 8 is an X-ray single-crystal structure of IE in an embodiment of the disclosure. The thermal ellipsoids were drawn at the 30% probability level, and the hydrogen atoms were omitted for clarity.

DETAILED DESCRIPTION OF THE DISCLOSURE

(I) DEFINITIONS

[0020] The term "diamino carbene ligand" as used herein refers to a ligand for palladium which contains a carbon atom having six valence electrons (carbene), in which the carbene carbon atom is bonded to two amino groups. Two of the six valence electrons on the carbene carbon are present as a lone pair, and it is the lone pair which co-ordinates with the palladium atom in the cationic palladium precatalyst in the compounds of the formulae (I) and (la). The amino groups may be unsubstituted or substituted with, for example, alkyl groups, alkenyl groups, alkynyl groups, or cycloalkyi groups (all of which are substituted or unsubstituted), or the amino groups may form, together, a heterocyclic ring, or the substituents on the amino groups may form a ring, together with the nitrogen atom.

[0021] The term "anionic ligand" as used herein refers to any negatively charged ligand that is commonly used as a ligand in metal catalysis, such as halo (such as chloro), H, Ci _-6 alkoxy and carboxyl (C(=O)O).

[0022] The term "neutral Lewis base" as used herein refers to any neutral two electron donor which are optionally present to fulfill the valence requirements of the palladium metal. Examples of neutral Lewis bases include, but are not limited to, acetonitrile and pyridine.

[0023] The term "combined anionic and neutral ligand" as used herein refers to any ligand which can act as both an anionic ligand as defined above, as well as a neutral Lewis base, also as defined above. The combined anionic and neutral ligand therefore contains both an anionic moiety (such as an alkoxy, aryloxy or aryl type moiety) and also a neutral moiety which can donate electrons to the palladium to optionally fulfill the valence requirements, such as, but not limited to, an amino group moiety.

[0024] The term "non-coordinating anion", "mono-anion" or "di-anion", or weakly co-ordinating anion, as used herein refers to any negatively charged ion which acts as a counterion to the positively charged palladium atom. The non-coordinating anion is either a mono-anion or a di-anion, depending on the overall charge of the palladium complex. Examples of non-coordinating mono-anions include, but are not limited to BF ₄ , B(CeF ₅ ) ₄ , or carboranes. Example of non-coordinating di-anions include, but are not limited to CO3, SO ₄ and C2O4. It will be understood that depending on the overall charge of the palladium complex, for example a charge of +2, two mono-anions, which are optionally the same or different, balance the positive charge of the palladium, or one alternatively, one di-anion. [0025] The term "chiral" as used herein refers to any of the compounds of the present disclosure, for example compounds of the formulae (I), (la) or (II), which contain at least one asymmetric center (chiral atom or chiral center) and thus occur in two non-superimposable mirror-image forms as enantiomers. The term also includes compounds having more than one asymmetric center, such as diastereomers.

[0026] The term "Ci _-W alkyl" as used herein means straight and/or branched chain, saturated alkyl groups containing from one to "w" carbon atoms and includes (depending on the identity of w) methyl, ethyl, propyl, isopropyl, n- butyl, s-butyl, isobutyl, t-butyl, 2,2-dimethylbutyl, n-pentyl, 2-methylpentyl, 3- methylpentyl, 4-methylpentyl, n-hexyl and the like, where the variable w is an integer representing the largest number of carbon atoms in the alkyl group.

[0027] The term "C ₂ - _w alkenyl" as used herein means straight and/or branched chain, unsaturated alkyl groups containing from two to w carbon atoms and one to three double bonds, and includes (depending on the identity of w) vinyl, allyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, 2- methylbut-1-enyl, 2-methylpent-1-enyl, 4-methylpent-1-enyl, 4-methylpent-2- enyl, 2-methylpent-2-enyl, 4-methylpenta-1 ,3-dienyl, hexen-1-yl and the like, where the variable w is an integer representing the largest number of carbon atoms in the alkenyl group.

[0028] The term "C ₂ -walkynyl" as used herein means straight and/or branched chain, unsaturated alkyl groups containing from two to w carbon atoms and one to three bonds, and includes (depending on the identity of w) propargyl, 2-methylprop-1-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 2-methylbut- 1-ynyl, 2-methylpent-1-ynyl, 4-methylpent-1-ynyl, 4-methylpent-2-ynyl, 2- methylpent-2-ynyl, 4-methylpenta-1 ,3-diynyl, hexyn-1-yl and the like, where the variable w is an integer representing the largest number of carbon atoms in the alkynyl group.

[0029] The term "C _3-w cycloalkyl" as used herein means a monocyclic, bicyclic or tricyclic saturated carbocylic group containing from three to w carbon atoms and includes (depending on the identity of w) cyclopropyl, cyclobutyl, cyclopentyl, cyclodecyl and the like, where the variable w is an integer representing the largest number of carbon atoms in the cycloalkyl group.

[0030] The term "aryl" as used herein means a monocyclic, bicyclic or tricyclic aromatic ring system containing from 6 to 14 carbon atoms and at least one aromatic ring and includes phenyl, naphthyl, anthracenyl, 1 ,2- dihydronaphthyl, 1 ,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl and the like.

[0031] The term "heteroaryl" as used herein means a monocyclic, bicyclic or tricyclic ring system containing one or two aromatic rings and from 5 to 14 atoms of which, unless otherwise specified, one, two, three, four or five are heteroatoms independently selected from N, NH, N(Ci _-6 alkyl), O and S and includes thienyl, furyl, pyrrolyl, pyrididyl, indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, benzothienyl and the like.

[0032] The term "halo" as used herein means halogen and includes chloro, flouro, bromo and iodo.

[0033] The term "ring system" as used herein refers to a carbon-containing ring system, that includes monocycles, fused bicyclic and polycyclic rings and bridged rings. Where specified, the carbons in the rings may be substituted or replaced with heteroatoms.

[0034] In understanding the scope of the present disclosure, the term "comprising" and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, groups, integers, and/or steps, but do not exclude the presence of other unstated features, elements, components, groups, integers and/or steps. The foregoing also applies to words having similar meanings such as the terms, "including", "having" and their derivatives. Finally, terms of degree such as "substantially", "about" and "approximately" as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the word it modifies. (II) COMPOUNDS OF THE DISCLOSURE

[0035] The present disclosure relates to cationic Pd(ll) pre-catalysts which when converted to the active catalyst, have been determined to be active catalysts in organic reactions, such as coupling reactions or hydroamination reactions, including Suzuki-Miyaura coupling reactions, Negishi coupling (both sp ² -sp ² and sp ² -sp ³ ), Sonogashira coupling, Heck-Mizoroki coupling and Hartwig-Buchwald amination.

[0036] Accordingly, the present disclosure includes a cationic palladium pre-catalyst compound of the formula I:

[Pd (X) _q (LB) _n (LBX)t(DC)nY (I) wherein

DC is a diamino carbene ligand,

X is any anionic ligand,

LB is any neutral Lewis base,

LBX is a combined anionic and neutral ligand,

Y is any non-coordinating anion,

q is 0 or 1,

n is 0 to 3,

t is 0 or 1 ,

r is 1 or 2,

m is 1 or 2,

p is 1 or 2,

wherein the sum of q + r is 2 or t + r is 2,

when t is 1 , q is 0,

when r is 1 , m and p are both 1 , and

when r is 2, either (i) m is 2 and p is 1 , or (ii) m is 1 and p is 2,

wherein when p is 2, Y is the same or different.

[0037] In another embodiment, the present disclosure also includes dimeric forms of the pre-catalyst compounds having the formula (la)

[Pd (X) _p (LB)n (LBX)t (DC)] ₂ ^a+ [V-] _u [Z ² -] _y (la) wherein

DC is a diamine- carbene ligand,

X is any anionic ligand,

LB is any neutral Lewis base,

LBX is a combined anionic and neutral ligand,

V is any non-coordinating mono-anion,

Z is any non-coordinating di-anion

q is 0 or 1 ,

n is 0 to 3,

t is 0 or 1 ,

a is 2 or 4,

u is 0, 2 or 4,

y is 0, 1 or 2,

wherein the sum of q + a is 3 or 4, or t + a is 3 or 4,

when t is 1 , q is 0,

when a is 2, either (i) u is 2 and y is 0; or (ii) u is 0 and y is 1 ; or

when a is 4, either (i) u is 4 and y is 0; (ii) u is 2 and y is 1 ; or (iii) u is 0 and y is 2;

wherein when u is 2 or 4, V is the same or different, and

when y is 2, Z is the same or different.

[0038] In one embodiment, the precatalyst compounds of the formulae (I) or (la) are chiral or achiral, optionally chiral.

[0039] In another embodiment of the disclosure, the diamino carbene ligand is a compound of the formula (II):

wherein R ¹ , R ² , R ³ and R ⁴ are independently selected from H, C-i _-2 oalkyl, C _2-2 oalkenyl, C _2-2 oalkynyl, C3- ₂ ocycloalkyl, heteroaryl and aryl, each group being optionally substituted, or

R and R ² and/or R ³ and R ⁴ are linked to form, together with the nitrogen atom to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 3 to 20 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NCi-6alkyl, and/or

R and R ³ or R ² and R ⁴ are linked to form, together with the nitrogen atoms to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 3 to 20 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NCi-6alkyl,

the optional substituents on R ¹ , R ² , R ³ and R ⁴ are independently selected from one or more of Ci _-6 alkyl, halo, halo-substituted Ci _-6 alkyl, C _3- iocycloalkyl, aryl and heteroaryl.

[0040] In another embodiment, R ¹ , R ² , R ³ and R ⁴ are independently selected from H, Ci.i ₀ alkyl, C _2- i ₀ alkenyl, C _2- i ₀ alkynyl, C _3- iocycloalkyl, heteroaryl and aryl, each group being optionally substituted. In another embodiment, R ¹ , R ² , R ³ and R ⁴ are independently selected from H, Ci-ealkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _3-6 cycloalkyl, heteroaryl and aryl, each group being optionally substituted. In another embodiment, R ¹ , R ² , R ³ and R ⁴ are independently selected from H, C _1-4 alkyl, C ₂ - ₄ alkenyl, C _2-6 alkynyl, C5- ₆ cycloalkyl and phenyl, each group being optionally substituted. In another embodiment, R ¹ , R ² , R ³ and R ⁴ are independently selected from H, Ci^alkyl, and phenyl, each group being optionally substituted. In another embodiment, R ¹ , R ² , R ³ and R ⁴ are independently selected from H, methyl, ethyl, propyl, isopropyl, butyl and phenyl, wherein phenyl is substituted at least once, optionally twice, optionally three times by C-i _-4 alkyl. In another embodiment, R , R ² , R ³ and R ⁴ are isopropyl. In another embodiment, R ¹ , R ² , R ³ and R ⁴

are independently selected from an

[0041] In another embodiment, R and R ² or R ³ and R ⁴ are linked to form, together with the nitrogen atom to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 3 to 10 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NC-i. ₆ alkyl. In another embodiment, R ¹ and R ² or R ³ and R ⁴ are linked to form, together with the nitrogen atom to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 5 to 10 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and Nd- ₆ alkyl. In another embodiment, R ¹ and R ² or R ³ and R ⁴ are linked to form, together with the nitrogen atom to which they are attached, an optionally substituted monocyclic, saturated or unsaturated ring system that contains 5 to 6 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NC _1-6 alkyl.

[0042] In another embodiment, R ¹ and R ³ or R ² and R ⁴ are linked to form, together with the nitrogen atoms to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 3 to 10 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NCi. ₆ alkyl. In another embodiment, R ¹ and R ³ or R ² and R ⁴ are linked to form, together with the nitrogen atoms to which they are attached, an optionally substituted monocyclic or polycyclic, saturated or unsaturated ring system that contains 5 to 10 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NC-i. ₆ alkyl. In another embodiment, R ¹ and R ³ or R ² and R ⁴ are linked to form, together with the nitrogen atoms to which they are attached, an optionally substituted monocyclic, saturated or unsaturated ring system that contains 5 to 6 carbon atoms, of which one or more of the carbon atoms is optionally replaced with a heteromoiety selected from O, S, NH and NCi-6alkyl.

[0043] In another embodiment of the disclosure, the compound of the

formula (II) is

, the compound of the formula (II) is

[0045] In another embodiment, the optional substituents on R , R ² , R ³ and R ⁴ are independently selected from one or more, optionally one to five, of Ci- ₄ alkyl, halo, halo-substituted Ci _-4 alkyl, C3-6cycloalkyl, aryl and heteroaryl. In another embodiment, the optional substituents on R ¹ , R ² , R ³ and R ⁴ are independently selected from one or more, optionally one to five, of C-i _-2 alkyl, halo, halo-substituted Ci-2alkyl, C _5- 6cycloalkyl and phenyl.

[0046] In another embodiment of the disclosure, the compound of the formula (II) is chiral or achiral, optionally chiral.

[0047] In an embodiment of the disclosure, X is any suitable anionic ligand, including, for example, halo, H, Ci-6alkoxy and carboxyl. In another embodiment, X is CI.

[0048] In another embodiment, LB is any suitable neutral Lewis base, for example any neutral two electron donor, for example acetonitrile or pyridine. [0049] In another embodiment, LBX is any suitable compound that possesses both an anionic moiety and a Lewis base moiety. In another embodiment, LBX is

^•

[0050] In another embodiment, Y is any non-coordinating counter anion, including, for example, BF ₄ , B(CeF ₅ ) , a carborane, CO3, S0 ₄ and C ₂ 0 ₄ .

[0051] In an embodiment of the disclosure, the compound of the formula

2[BF ₄ ]- [0052] In another embodiment of the disclosure, the compound of the formula (la) is

(III) PREPARATION OF THE COMPOUNDS OF FORMULAE (I) AND (la)

[0053] In another embodiment of the disclosure, the compounds of the formulae (I) and (la) are prepared by the abstraction of an anionic ligand from the corresponding neutral precursors. Accordingly, in an embodiment, the compounds of the formulae (I) and (la) are prepared from the corresponding neutral compounds [Pd (X) _q (LB) _n (LBX), (DC)] or [Pd (X) _q (LB) _n (LBX), (DC)] ₂ , wherein DC, X, LB, LBX, n and t have the same definitions as described above, and q or t is an integer between 0 and 2. [0054] For example, in an embodiment, neutral precursors of pre-catalyst

[0055] In another embodiment of the disclosure, the neutral precursors of the cationic palladium pre-catalysts compounds of the formula (I) or (la) are prepared, for example, as shown in Scheme 1.

[0056] In another embodiment of the disclosure, neutral precursors comprising a combined anionic and neutral ligand are prepared, for example, as shown in Scheme 2.

[0057] In another embodiment, the compounds of the formula (I) and (la) are prepared from the corresponding neutral precursors, for example, by anion abstraction of one or two anionic ligands, with the salt of a weakly or non-coordinating anion, generally as shown in Schemes 3, 4 and 5.

Scheme 3

X: BF ₄ , [B(C ₆ F ₅ ) ₄ ], carborane Scheme 4

[0058] In another embodiment, the compounds of the formula and (la) are prepared generally as shown in Scheme 6.

Scheme 6

[0059] In another embodiment, while specific groups for DC, X, LB and LBX are shown above in Schemes 1-6, a person skilled in the art would appreciate that other equivalent groups as described herein can be substituted to obtain the compounds of the formula (I) and (la), in addition to the precursors of these compounds.

(IV) METHODS OF THE DISCLOSURE

[0060] The present disclosure also includes a method of performing palladium-catalyzed organic synthesis reactions comprising contacting substrates for the organic synthesis reaction with cationic palladium precatalyst compounds of the formulae (I) or (la) as defined above in the presence of a base under conditions for performing the organic synthesis reaction, and optionally isolating one or more products from the organic synthesis reaction.

[0061] In an embodiment of the disclosure, the organic synthesis reaction is any reaction the benefits from the presence or use of a palladium catalyst, for example, but not limited to, cross-couplings and hydroaminations, such as Suzuki-Miyaura coupling reactions, Negishi coupling (both sp ² -sp ² and sp ² - sp ³ ), Sonogashira coupling, and Heck-Mizoroki coupling, as well as Hartwig- Buchwald aminations. [0062] In an embodiment of the disclosure, the organic synthesis transformation is an asymmetric or chiral synthesis reaction (i.e. provides one enantiomer in excess of the other).

[0063] In an embodiment of the disclosure, the active palladium catalysts are generated in situ in solution from the compound of the formulae (I) or (la) in the presence of a base and the resulting catalyst solution is added to the appropriate starting materials for the organic synthesis transformation.

[0064] The following non-limiting examples are illustrative of the present disclosure:

(V) EXAMPLES

Materials and Methods

[0065] Unless indicated otherwise, all chemicals were obtained from Sigma-Aldrich and were used without any other purification unless otherwise specified. All coupling reactions were carried out under inert atmosphere (nitrogen or argon). ¹ H and ¹³ C NMR spectra were recorded using 200 MHz, 300, 400 and 500 MHz spectrometers. Proton chemical shifts were internally referenced to the residual proton resonance in CDC (δ 7.26). Carbon chemical shifts were internally referenced to the deuterated solvent signals in CDCb (δ 77.2).

Example 1: Synthesis of Precursors

(i) Precursor A

[0066] To a 100 mL flask was added PdCI ₂ (0.91 g, 5.17 mmol), bis(diisopropylamino)carbene (1.0 g, 4.7 mmol) and pyridine (50 ml) was used to dissolve it. The solution was clear at the beginning and the precipitate slowly formed, together with unreacted PdCI ₂ . PdCI ₂ slowly disappeared during the course of the reaction. The reaction mixture was stirred for 18 hours at room temperature. Then the solvent was completely removed. It was then re-dissolved in CH2CI2 and H ₂ 0 was added to wash the product. It was separated, dried over MgS0 ₄ , filtered and concentrated. Et.20 (ca. 200 mL) was then added to form a pale yellow solid. The solid was then filtered off, and the filtrate was concentrated and recrystallized from hexanes to obtain a pale yellow solid as the final product. Yield: 1 .4 g, 63%. ¹ H NMR (200 MHz, CD2CI2): d8.94 (2H, d, pyridine), 7,76 (1 H, t, pyridine), 7.33 (2H, dd, pyridine), 4.83 (4H, m, (CH ₃ ) ₂ CH ₂ ), 1.63 (24H, d, CH ₃ ).

[0067] The X-ray crystal structure of Precursor A is shown in Figure 1.

(ii) Precursor B

[0068] To a 100 mL flask was added Di^-chlorobis(N,N)- dimethylbenzylamine)-dipalladium (0.26 g, 0.47 mmol), bis(diisopropylamino)carbene (0.2 g, 0.94 mmol) and the solid mixture was dissolved in THF. The solution was allowed to stir for 18 hours. Then the solvent was concentrated and the product was recrystallized from CH ₂ CI ₂ /hexanes as a pale yellow solid. Yield: 0.4 g, 86%. ¹ H NMR (200 MHz, CD2CI2): d 6.95 (2H, d, Ph), 6.90 (1 H, m, Ph), 6.80 (1 H, m, Ph), 4.74 (4H, m, (CH ₃ ) ₂ CH ₂ ), 3.77 (2H, s, CH ₂ ), 2.66 (6H, s, CH ₃ ), 1.60 (12H, d, CH ₃ ), 1.49 (12H, d, CH ₃ ).

[0069] The x-ray crystal structure of Precursor B is shown in Figure 2. (Hi) Precursor C

[0070] To a flask was added 1-(2,6-diisopropylphenyl)-3-(2,4,6- trimethylphenyl)-4,5-dihydroimidazolium chloride (0.14 g, 0.36 mmol), the Di- μ-chlorobis(N,N)-dimethylbenzylamine)dipalladium (0.10 g, 0.18 mmol) and THF was added to dissolve it. The reaction mixture was allowed to reflux for 18 hours. Then the solution was cooled down and filtered to remove the insoluble solid. Then the solvent was concentrated and the remaining solid was recrystallized from hexanes to obtain a pale yellow solid. Yield: 0.15 g, 66%. ¹ H NMR (200 MHz, CD ₂ CI ₂ ): δ 6.65 - 7.35 (9H, m, Ph), 4.05 (4H, m, - NCH ₂ CH ₂ N-), 3.58 (2H, m, (CH ₃ ) ₂ CH ₂ ), 3.40 (2H, s, CH ₂ ), 2.62 (6H, S, CH ₃ ), 2.25 (12H, m, CH ₃ ), 1.50 (3H, d, CH ₃ ), 1.22 (3H, m, CH ₃ ), 0.83 (3H, d, CH ₃ ).

[0071] The X-ray crystal structure of Precursor C is shown in Figure 3. (iv) Precursor D

[0072] To a 100 ml_ flask was added PdCI ₂ (0.092 g, 0.518 mmol), bis(diisopropyl)carbene (0.1 g, 0.47 mmol), THF (20 ml) and 1- methylimidazole (0.113 ml, 1.4 mmol, 3 equiv.) was added to dissolve it. The solution was clear at the beginning and the precipitate slowly formed, together with unreacted PdCI ₂ . PdCI ₂ slowly disappeared during the course of the reaction. The reaction mixture was stirred for 18 hours at room temperature. Then the solvent was completely removed. It was then re-dissolved in CH ₂ Cl ₂ and H ₂ 0 was added to wash the product. It was separated, dried over MgS0 ₄ , filtered and concentrated. Et ₂ 0 (ca. 200 ml_) was then added to form a pale yellow solid. The solid was then filtered off, and the filtrate was concentrated and recrystallized from hexanes to obtain a pale yellow solid as the final product. Yield: 0.15 g, 70%. ¹ H NMR (200 MHz, CD ₂ CI ₂ ): δ 7.94 (1 H, s, imidazole), 7.36 (1 H, s, imidazole), 6.79 (1 H, s, imidazole), 4.80 (4H, m, (CH ₃ ) ₂ CH ₂ ), 3.64 (3H, s, CHr ^' imidazole), 1.57 (24H, d, CH ₃ ). Example 2: Preparation of Cationic Palladium PreCatalyst Compounds of

Formula (I)

(i) Compound IA

[0073] In the glovebox, Precursor B (0.1 g, 0.20 mmol) and AgBF ₄ (0.04 g, 0.02 mmol) was mixed together. Then CH2CI2 (4 ml_) was added to the solid mixture. The solution immediately turned to a cloudy pale brown solution with the formation of white precipitate. The mixture was allowed to stir for half hour and the solid was filtered off through a syringe filter. The solvent was then concentrated and hexanes was added to the residue. The solid that precipitated was filtered off and the filtrate was concentrated to give the product as a while solid. Yield: 0.049 g, 44%. ¹ H NMR (200 MHz, CD ₂ CI ₂ ): δ 6.81 - 6.95 (4H, m, Ph), 4.48 (4H, m, (CH ₃ ) ₂ CH ₂ ), 3.76 (2H, s, CH ₂ ), 2.68 (6H, s, CH ₃ ), 1.54 (24H, d, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): d -153 (s).

[0074] The X-ray crystal structure of compound IA is shown in Figure 4.

(77) Compound IB

[0075] In the glovebox, the Precursor C (0.096 g, 0.15 mmol) and AgBF ₄ (0.03 g, 0.15 mmol) were mixed together. Then CH ₂ CI ₂ (4 ml_) was added to the solid mixture. The solution immediately turned to a cloudy yellow solution with the formation of white precipitate. The mixture was allowed to stir for half hour and the solid was filtered off. The filtrate was then concentrated, and the product was recrystallized from hexanes as a pale yellow solid. Yield: 0.086 g, 82%. ¹ H NMR (200 MHz, CD ₂ CI ₂ ): δ 7.45 (2H, m, Ph), 7.35 (2H, d, Ph), 6.64 - 6.90 (5H, m, Ph), 4.09 (4H, m, -NCH ₂ CH ₂ N-), 3.40 (2H, s, CH ₂ ), 3.25 (2H, m, (CH ₃ ) ₂ C V ₂ ), 2.38 (6H, s, CH ₃ ), 2.20 (9H, s, CH ₃ ), 1.23 (12H, d, CH ₃ ). ⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -153 (s).

[0076] The X-ray crystal structure of compound IB is shown in Figure 5.

(Hi) Compound IC

[0077] In the glovebox, a small vial was charged with dichloro(pyridine)[frans-(1 ,3-bis(2,6-diethylphenyl)imidazolin-2- ylidene)]palladium(ll) (50 mg, 0.083 mmol) and AgBF ₄ (33 mg, 0.165 mmol) and CH ₂ CI ₂ was added to dissolve the mixture. 4 equiv. of pyridine (0.027 mL) was then added to the solution and the solution was allowed to stir overnight. The solvent was then concentrated to obtain a colorless solid. Yield: 58 mg, 81 %. H NMR (300 MHz, CD ₂ CI ₂ ): d 6.90 - 8.60 (20H, m, Ph and pyridine), 4.06 (4H, m, -NCH ₂ CH ₂ N-), 3.18 (2H, m, (CH ₃ ) ₂ CH ₂ ), 2.25 (3H, s, CH ₃ ), 2.12 (6H, s, CH ₃ ), 1.22 (12 H, m, (CH ₃ ) ₂ CH ₂ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -153 (s).

[0078] The X-ray crystal structure of compound IC is shown in Figure 6.

(iv) Compound ID

[0079] In the glovebox, a small vial was charged with the precursor A (50 mg, 0.106 mmol) and AgBF (42 mg, 0.212 mmol) and CH ₂ CI ₂ was added to dissolve the mixture. 4 equiv. of pyridine (0.034 mL) was then added to the solution and the solution was allowed to stir overnight. The solvent was then concentrated to obtain a colorless solid. Yield: 69 mg, 91 %. ¹ H NMR (300 MHz, CD ₂ CI ₂ ): 6 7.30 - 9.10 (15H, m, pyridine), 3.65 (4H, m, (CH ₃ ) ₂ CH ₂ ), 1.38 (24H, m, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -153 (s).

[0080] The X-ray crystal structure of compound ID is shown in Figure 7. (v) Compound IE

[0081] To a small vial was added the compound A (49 mg, 0.09 mmol) and pyridine (4 mL) was added to dissolve the compound. The solution was allowed to stir overnight. The solvent was then concentrated and the product recrystallized from ether to obtain a white solid, Yield: 44 mg, 78%. ¹ H NMR (200 MHz, CD ₂ CI ₂ ): δ 8.70 (2H, d, pyridine), 8.00 (1 H, m, pyridine), 7.62 (2H, m, pyridine), 7.00 (4H, m, Ph), 5.14 (4H, m, (CH ₃ ) ₂ CH ₂ ), 3.82 (2H, s, CH ₃ ), 2.28 (6H, s, CH ₃ ), 1.45 (12 H, d, CH ₃ ), 1.25 (12H, d, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -153 (s).

[0082] The x-ray crystal structure of compound IE is shown in Figure 8.

(vi) Compound IF

[0083] To a small vial was added the compound IB (86 mg, 0.13 mmol) and pyridine (4 mL) was added to dissolve the compound. The solution was allowed to stir overnight. The solvent was then concentrated and the product recrystallized from ether to obtain a white solid, Yield: 81 mg, 84%. ¹ H NMR (200 MHz, CD ₂ CI ₂ ): δ 6.60 - 7.80 (14H, m, pyridine and Ph), 4.2 (6 H, br m, CH ₂ ), 3.45 (2H, m, CH ₂ ), 2.25 (6H, s, CH ₃ ), 1.84 (6H, d, CH ₃ ), 1.50 (3H, s, CH ₃ ), 1.20 (12H, m, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -153 (s).

(vi) Compound IG

[0084] In the glovebox, a small vial was charged with the Precursor A (50 mg, 0.106 mmol) and [Li(OEt ₂ ) ₂ .5][B(C ₆ F5)4] (100 mg, 0.1 17 mmol) and CH ₂ CI ₂ was added to dissolve the mixture. 1.1 equiv. of pyridine (~0.01 mL) was then added to the solution and the solution was allowed to stir overnight. The precipitate was then filtered off and the filtrate was then concentrated and recrystallized from hexanes to obtain a pale yellow solid. Yield: 100 mg, 79%. ¹ H NMR (300 MHz, CD ₂ CI ₂ ): δ 7.30 - 8.50 (10H, m, pyridine), 5.10 (4H, m, (CH ₃ ) ₂ CH ₂ ), 1.75 (12H, d, CH ₃ ), 1.30 (12H, d, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): 6 -133 (8F, s), -164 (8F, s), -168 (4F, s). (vii) Compound IH

[0085] In the glovebox, a small vial was charged with the palladium compound (0.20 g, 0.33 mmol) and [Li(OEt ₂ ) ₂ .5][B(C ₆ F5)4] (302 mg, 0.364 mmol) and CH ₂ CI ₂ was added to dissolve the mixture. 1 .1 equiv. of pyridine (~0.03 mL) was then added to the solution and the solution was allowed to stir overnight. The precipitate was then filtered off and the filtrate was then concentrated and recrystallized from hexanes to obtain a pale yellow solid. Yield: 440 mg, 99%. ¹ H NMR (300 MHz, CD ₂ CI ₂ ): δ 6.85 - 8.50 (15H, m, pyridine and Ph), 4.0 (4H, m, CH ₂ ), 2.6 (2H, s, (CH ₃ ) ₂ CH ₂ ), 1.80 (3H, s, CH ₃ ), 1.60 (3H, s, CH ₃ ), 1 .25 (12H, m, CH ₃ ), 0.8 (6H, m, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -133 (8F, s), -164 (8F, s), -168 (4F, s).

(viii) Compound II

[0086] In the glovebox, dichloro(pyridine)[frans-(1 ,3-bis(2,6- diethylphenyl)imidazolin-2-ylidene)]palladium(ll) (500 mg, 0.825 mmol) and AgBF ₄ (160 mg, 0.825 mmol) were stirred in CH ₂ CI ₂ (20 mL) for 20 minutes. The resulting yellow solution was filtered through celite and evaporated to dryness. A beige-yellow solid was obtained. Yield: 400 mg, 74%. ¹ H NMR (300 MHz, CD ₂ CI ₂ ): δ 7.90 - 6.80 (20H, m, pyridine and Ph), 4.20-3.80 (8H, m, CH ₂ ), 2.40-2.20 (4H, s, CH), 1.60-0.80 (8H, m, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -154 (s). (vii) Compound IJ

[0087] In air, compound II (100 mg, 0.150 mmol) and pyridine (4 mL) were stirred overnight. The resulting yellow solution was evaporated to dryness. The resulting bright yellow solid was recrystallized with CI-bCN/Hexanes. Yield: 90 mg, 90%. ¹ H NMR (300 MHz, CD ₂ CI ₂ ): δ 7.90 - 6.80 (15H, m, pyridine and Ph), 4.20-3.80 (4H, m, CH ₂ ), 2.60-1.80 (2H, m, CH), 1 .60-0.80 (21 H, m, CH ₃ ), ⁹ F NMR (282 MHz, CD ₂ CI ₂ ): δ -153 (s).

Example 3: Synthesis of Comp

[0088] To a 100 mL flask was added Di^-chlorobis(N.N)- dimethylbenzylamine)dipalladium (0.97 g, 1.76 mmol) and 2 equiv. of AgBF ₄ (0.699 g, 3.52 mmol) and CH ₂ CI ₂ was added to dissolve it. 4 equiv. of pyridine (0.567 ml, 7.04 mmol) was added. The precipitate formed was filtered off and the filtrate was concentrated to give a white color solid. Yield: 1.67 g, 82%. ¹ H NMR (300 MHz, CD ₂ CI ₂ ): δ(, 2H, m, Py), 6.80 - 7.95 (1 1 H, m, Ph and Py), 6.00 (1 H, d, Ph), 4.12 (2H, s, CH ₂ ), 2.62 (6H, s, CH ₃ ). ¹⁹ F NMR (282 MHz, CD ₂ CI ₂ ): 6 -153 (s). Example 4: Synthesis of

4

[0089] This compound was synthesized according to Athe literature method. ³ Yield: 80%.

Example 5: Synthesis of Co

[0090] The oxygen-containing palladacycle precursor was synthesized according to the literature method. ⁴ To a flask was added the palladacycle precursor (0.688 g, 1.177 mmol) and 2 equiv. of the free ADC-carbene (0.5 g, 2.35 mmol) and the solid mixture was dissolved in THF. The solution was allowed to stir overnight. The workup procedure was the same as B. Pale red solid. Yield: 0.15 g, 25%. H NMR (200 MHz, CD ₂ CI ₂ ): d 7.05 (1 H, m, Ph), 6.86 (1 H, d, Ph), 6.68 (1 H, d, Ph), 6.55 (1 H, m, Ph), 5.22 (4H, m, (CH ₃ ) ₂ CH ₂ ), 3.18 (2H, s, CH ₂ ), 2.59 (6H, s, CH ₃ ), 1.40 (24H, d, CH ₃ ).

Example 6: General procedure for Suzuki-Miyaura coupling

[0091] To a solution of an aryl halide (0.5 mmol), aryl boronic acid (0.60 mmol) and potassium (or cesium) carbonate (1 mmol, 2.0 equiv) in 1 ,4- dioxane or alcoholic solvent (2.0 ml_) was added [Pd(CI)(NHC)(py)] ₂ ⁺ BF ^" (0.01 mmol, 2 mol%) under nitrogen or argon gas. The reaction was then stirred at 80°C under reflux conditions for 16 hours, the mixture was then cooled to room temperature, filtered and concentrated in vacuo, the residue was subsequently purified by silica gel chromatography (hexanes/EtOAc or hexanes/ether). The isolated products were characterized by ¹ H and ¹³ C NMR spectroscopy.

Discussion

[0092] Various structural motifs (i.e. bridging halogens, pyridine coordination to Pd-NHC complexes; and also the newly introduced ionic character) have been incorporated into the precatalysts reported herein. In Suzuki-Miyaura coupling the dimeric II, demonstrated good catalytic activity (as seen in Table 1 ). II was also used to couple a number of different substrate (as seen in Table 2). The use of CS2CO3 as a base instead of K2CO3 was investigated (entry 14 and 15). The use of different alcoholic solvents was also investigated (Tables 3 and 4).

Example 7: General procedure for Kumada coupling

[0093] To a solution of aryl Grignard reagent (0.6 mmol) and organo halide (0.5 mmol) in THF was added 0.001 mmol of catalyst II under argon at room temperature. The reaction mixture was then stirred for 2 hours. After this time the reaction mixture was diluted with diethyl ether and filtered. The solvent was removed in vacuo and the residue was purified by silica gel chromatography.

Example 8: General procedure for Negishi coupling

[0094] To a solution of organozinc halide (0.6 mmol) and organo halide (0.5 mmol) in THF was added 0.001 mmol of catalyst II under argon at room temperature. The reaction mixture was then stirred for 2 hours. After this time the reaction mixture was diluted with diethyl ether and filtered. The solvent was removed in vacuo and the residue was purified by silica gel chromatography. Discussion

[0095] The results are shown in Tables 5 and 6. II was found to give good conversion at room temperature in THF. The addition of LiBr did not increase the sp ² -sp ² coupling (Table 5), but the conversions were doubled for the sp ² - sp ³ coupling (Table 6).

Example 9: General procedure for Sonogashira coupling

[0096] To a solution of organo halide (0.5 mmol), terminal alkyne (0.6 mmol) and a base (CS2CO3 / triethylamine), was added the catalyst II (0.01 mmol), in some cases Cul (0.01 mmol) was added as a co-catalyst and/or PPh ₃ (0.5 mmol) was added as a co-ligand, and the reaction was purged with argon, heated to 80°C and stirred at this temperature for 16 hours. The reaction mixture was allowed to cool to room temperature, diluted with diethyl ether, filtered, and the solvent removed in vacuo. The residue was purified by silica gel chromatography.

Discussion

[0097] The results are shown in Table 7. It was found that the addition of PP i3 as a co-ligand increases the yields while the addition of Cul in most cases leads to homocoupled product. DMF was the only solvent used with Cul that did not give homocoupled product. Changing the base from CS2CO3 to triethylamine also led to the homocoupled product.

Example 10: General procedure for Heck-Mizoroki coupling

[0098] A solution of the alkene (0.50 mmol), aryl halide (0.5 mmol), [Pd(CI) ₂ (NHC)(py)] ₂ II (0.01 mmol) and potassium carbonate (1 mmol) in 1 ,4- dioxane (2.0 ml_), in a pressure tube, was purged with argon, the pressure tube was then sealed with a screw cap; and the reaction was stirred for 16 hours at 00 °C. The reaction mixture was then cooled to room temperature, filtered and concentrated in vacuo to afford the crude aryl-alkenyl derivative, which was subsequently purified by silica gel chromatography (hexanes/EtOAc or hexanes/ether). The results are shown in Table 8. Example 11: Characterization Data

(i) Biphenyl

[0099] Isolated as colorless solid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 7.71 (4H, d, J = 7.8 Hz), 7.55 (4H, t, J = 7.5 Hz), 7.45 (2H, t, J = 7.2 Hz).

(ii) 4-m

[00100] Isolated as yellow solid; H NMR (CDCI ₃ , 300 MHz): δ 7.51 (2H, d, J = 8.7 Hz), 7.45 (2H, d, J = 7.8 Hz), 7.23 (2H, d, J = 7.8 Hz), 6.97 (2H, d, J = 8.7 Hz), 3.85 (3H, s), 2.39 (3H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 159.19, 138.24, 136.62, 134.02, 129.72, 128.24, 126.87, 1 14.42, 55.63, 22.99. -methoxybiphenyl

[00101] Isolated as a colourless solid; H NMR (CDCb, 300 MHz): δ 7.55 - 7.61 (4H, m), 7.42 - 7.48 (2H, tt), 7.34 - 7.36 (1 H, tt), 6.99 - 7.03 (2H, dt), 3.87 (3H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 159.94, 141.16, 134.12, 129.04, 128.47, 127.05, 126.97, 114.54, 55.65.

(iv) 4 '-methoxybiphenyl-4-carbaldehyde

[00102] Isolated as dark yellow solid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 10.04 (1 H, s), 7.93, (2H, d, J = 8.4 Hz), 7.72 (2H, d, J = 8.4 Hz), 7.60, (2H, d, J = 8.7 Hz), 7.01 , (2H, d, J = 8.7 Hz), 3.873 (3H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 192.57, 131 .02, 129.216 127.77, 1 15.21 , 56.13.

(v) 1-

[00103] Isolated as yellow solid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 8.01 , (2H, d, J = 8.7 Hz), 7.63, (2H, d, J = 8.7 Hz), 7.59, (2H, d, J = 8.7 Hz), 7.00, (2H, d, J = 8.7 Hz), 3.87 (3H, s), 2.63 (3H, s); ¹³ C NMR (CDC , 75 MHz): δ 198.18, 160.31 , 145.78, 135.67, 132.65, 129.36, 128.76, 127.03, 1 14.81 , 55.80, 31.13.

(vi) 4-fl ro-4'-methoxybiphenyl

[00104] Isolated as bright yellow solid; H NMR (CDCI3, 300 MHz): δ 7.46 - 7.52 (4H, m), 7.10 (2H, dd,J= 8.7 Hz, 8.7 Hz), 6.98 (2H, dd, J= 8.7 Hz, 8.7 Hz), 3.85 (3H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 163.90, 159.28, 137.15, 133.03, 128.36 (d, J=7.5 Hz), 128.23, 1 15.63 (d, J=20.1 Hz), 1 14.43, 55.56.

( vii) 2, 4 '-dimethoxybiphenyl

[00105] Isolated as colourless solid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 7.47 (2H, d, J = 8.7 Hz), 7.23 - 7.32 (2H, m), 6.93 - 7.03 (4H, m).

[00106] Isolated as yellow liquid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 7.28 - 7.21 (6H, m), 7.1 1 (2H, d, J = 6.6 Hz), 2.06 (6H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 141.68, 14.92, 129.90, 129.38, 127.25, 125.63, 29.83.

(ix) 1 , 1

[00107] Isolated as bright yellow; ¹ H NMR (CDCI ₃ , 300 MHz): δ 7.811 , (4H, d, J = 7.2 Hz), 7.596, (4H, d, J = 7.2 Hz), 2.597 (6H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 197.15, 135.89, 131.99, 129.95, 128.42, 26.68.

(x) (E)-methyl 3-(4-formylphenyl) acrylate

[00108] Isolated as dark yellow solid; H NMR (CDCI ₃ , 300 MHz): δ 10.03 (1 H, s), 7.90 (2H, d, J = 8.4 Hz), 8.04- 7.54 (3H, m), 6.56 (1 H, d, J = 15.9 Hz), 3.83 (3H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 191.56, 166.94, 143.26, 140.17, 137.32, 132.02, 131.44, 130.31 , 128.65, 121.1 1 , 52.13. (xi) (E)-methyl-3-(4-acethylphenyl)acrylate

[00109] Isolated as a yellow-orange solid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 7.97 (2H, d, J = 8.4 Hz), 7.71 (1 H, d, J = 15.9 Hz), 7.61 (2H, d, J = 8.4 Hz), 6.53 (1 H, d, J = 15.9 Hz), 3.83 (3H, s), 2.62 (3H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 143.45, 138.83, 138.16, 129.00, 128.28, 120.46, 52.05, 26.83.

(xii) (E)-methyl 3-(4-methoxy phenyl) acrylate

[00110] Isolated as pale yellow crystalline solid; ¹ H NMR (CDCI ₃ , 300 MHz): δ 7.65, (1 H, d, J = 15.9 Hz), 7.47, (2H, d, J = 9 Hz), 7.91 , (2H, d, J = 9 Hz), 6.31 , (1 H, d, J = 15.9 Hz), 3.84 (3H, s), 3.79 (3H,s); ³ C NMR (CDCI ₃ , 75 MHz): δ 167.93, 161.52, 144.68, 129.88, 127.25, 1 15.39, 1 14.45, 55.51 , 51.73.

(xiii) (E)-tert-butyl 3-(4-formylphenyl) acrylate

[00111] Isolated as a pale white solid; Ή NMR (CDCI ₃ , 300 MHz): δ 10.01 , (1 H, s), 7.87, (2H, d, J = 8.4 Hz), 7.64, (2H, d, J = 8.4 Hz), 7.59 (1 H, d, J = 15.9 Hz), 6.47 (1 H, d, J = 15.9 Hz), 1.53 (9H, s); ¹³ C NMR (CDCI ₃ , 75 MHz): δ 191.67, 165.86, 142.03, 140.70, 137.27, 130.38, 128.38, 123.73, 81.30, 28.42.

(xiv) (E)-tert-butyl 3-(4-methoxyphenyl)acrylate

[00112] Isolated as clear crystals; ¹ H NMR (CDCI ₃ , 500 MHz): δ 7.54, (1 H, d, J = 16 Hz), 7.46, (2H, d, J = 8.5 Hz), 6.89 (2H, d, J = 8.5 Hz), 6.24 (1 H, d, J = 16 Hz), 3.83 (3H, s), 1.53 (9H, s); ³ C NMR (CDCI ₃ , 75 MHz): δ 166.97, 161.37, 143.47, 129.81 , 127.66, 117.97, 1 14.51 , 80.50, 55.62, 28.51.

[00113] While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

[00114] All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term. Table 1 : Suzuki-Miyaura Coupling

Entry Catalyst % conv.

1 A 79

2 B 81

3 C 12

4 IA 44

5 IB 15

6 IC 29

7 ID 73

8 IE 64

9 IF 35

10 II 83

1 1 1J 86

12 No Cat., with base 0

13 No Cat., No base 27

14 II, No base 27

Table 2: Suzuki-Miyaura Coupling (Using Catalyst II)

%

Entry X R1 R2

conv.

1 CI 4-OMe 4-Me 34

2 Br 4-OMe 4-Me 48

3 Br 2-Me 1-napthalene 19

4 CI - 4-OMe 76

5 Br - 3-OMe 23

6 Br 4-CHO 4-OMe 24

7 Br 4-C(0)Me 4-OMe 9

8 Br 2-Me 4-F 5

9 Br 4-OMe 4-OMe 17

10 Br 4-OMe 2-OMe 14

11 Br 2-Me 2-Me 69

12 Br 4-C(O)Me 4-C(O)Me 48

13 Br 4-OMe 2-CF ₃ 44

14 ^a Br 4-OMe 4-Me 86

15 ^a CI - 4-OMe 88

16 Br - - 83

17 ^b CI - - 87 a:Cs2CO3 was used as a base instead of was used as solvent

Table 3: Suzuki-Miyaura Coupling (Using EtOH and 'PrOH as solvent)

Entry Catalyst EtOH 'PrOH

1 A 87 77

2 B 83 85

3 C 87 87

4 IA 90 82

5 IB 84 88

6 IC 88 87

7 ID 55 70

8 IE 86 82

9 IF 80 79

10 II 88 88

1 1 II 47 36

No Base

12 Base, No Cat. 35 11 Table 4: Suzuki-Miyaura Coupling (Comparision between EtOH and 'PrOH towards PhCI substrate)

16 hrs, 75°C

Entry Catalyst EtOH 'PrOH EtOH 'PrOH

PhBr PhBr PhCI PhCI

1 A 79 78 47 82

2 B 90 84 40 65

3 C 84 90 76 85

4 D 52 75 29 60

5 IA 81 88 14 63

6 II 90 90 73 87 Table 5: Sp ² -Sp ² Negishi Coupling Catalyzed by Compound II

Br

/^ ZnBr THF

^ _rt , 2hr

OMe

Entry Additives Conversion (%)

1 - 80

2 LiBr 83 Table 6: Sp ² -Sp ³ Negishi Coupling Catalyzed by Compound II

Conversion

Entry Additives

(%)

1 - 34

2 LiBr 62

Table 7: Sonogashira Coupling

Entry Solvent Cul PPh ₃ Conversion (%)

1 DMF Added - 17

2 DMF Added Added 41

3 Dioxane - - 26

4 DMF - Added 32

5 Dioxane - Added 47

6 DME _ Added 48

Table 8: Heck-Mizoroki Coupling

100°C

16h

Entry R' R" Conversion (%)

1 4-OMe 'Bu 50

2 4-CHO ^l Bu quant

3 ^* 4-CHO Me 23

4 ^* 4-C(0)Me Me 22

5 ^* 2-Me Me 1 1

^* : reactions run under reflux conditions FULL CITATION FOR DOCUMENTS REFERRED TO IN THE

SPECIFICATION

1. K. C. Nicolaou, P. G. Bulger, D. Sarlah, Angew. Chem. Int. Ed., 2005,

44, 4442-4489.

2. A. Yokoyama, H. Suzuki, Y. Kubota, K. Ohuchi, H. Higashimura and T.

Yokozawa, J. Am. Chem. Soc, 2007, 129, 7236-7237; S. L. Hargreaves, B. L Pilkington, S. E. Russell and P. A. Worthington, Tetrahedron Lett, 2000, 41 , 1653-1656.

3. A. De Leon, J. Pons, X. Solans and M. Font-Bardia, Acta Cryst, 2007, E63, m2164.

4. P. L. Alster, H. T. Teunissen, J. Boersma, A. L. Spek and G. van Koten, Organomet. 1993, 12, 4691.